Slate Path Capital’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Slate Path Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-7,927,998	Closed	-$160M	–	61
2025 Q3	$160M	Sell	7,927,998 -362,000	-4%	-$6.36M	2.48%	15
2025 Q2	$139M	Sell	8,289,998 -1,366,000	-14%	-$22M	2.4%	17
2025 Q1	$148M	Buy	9,655,998 +1,164,965	+14%	+$20.8M	2.68%	14
2024 Q4	$187M	Sell	8,491,033 -5,177,200	-38%	-$94.2M	3.38%	9
2024 Q3	$246M	Sell	13,668,233 -6,522,951	-32%	-$114M	3.79%	5
2024 Q2	$328M	Sell	20,191,184 -6,705,000	-25%	-$103M	6.25%	1
2024 Q1	$380M	Buy	26,896,184 +665,000	+3%	+$8.38M	7.52%	1
2023 Q4	$274M	Buy	26,231,184 +2,387,184	+10%	+$22.3M	6.08%	2
2023 Q3	$243M	Buy	23,844,000 +11,407,000	+92%	+$106M	6.78%	2
2023 Q2	$93.7M	Buy	+12,437,000	New	+$101M	3.42%	12

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Harel Insurance Investments & Financial Services Ramat Gan, Israel $21.3B AUM 44.31% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Lingotto Investment Management London, United Kingdom $5.74B AUM 42.24% 1-Year Est. Return

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Slate Path Capital's TEVA Position: Q4 2025 in Review

Slate Path Capital sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q4 2025, closing a stake of 7,927,998 shares — an estimated $160M sold.

Slate Path Capital first reported a position in TEVA in Q2 2023 and held it in 10 quarters. The position peaked at $380M in Q1 2024. 636 funds tracked by Wall St. Rank hold TEVA as of Q4 2025.

Slate Path Capital reported no remaining Teva Pharmaceutical Industries Limited position as of Q4 2025 after selling out during the quarter.
Slate Path Capital sold 7,927,998 Teva Pharmaceutical Industries Limited shares in Q4 2025, an estimated $160M.
Slate Path Capital first reported a position in Teva Pharmaceutical Industries Limited in Q2 2023 and held it in 10 quarters.
Slate Path Capital's Teva Pharmaceutical Industries Limited position peaked at $380M in Q1 2024.
636 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q4 2025.

Based on Slate Path Capital's 13F filing for Q4 2025, filed 17 Feb 2026.